SCHEMBL32689397

SCHEMBL32689397

O=C(O)CCCCCCCNS(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 4/20 0.61
ALDH1A1 P00352 4/20 0.60
TBXA2R P21731 1/20 0.60
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 1/20 0.58
THRB P10828 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
FABP4 P15090 3/20 0.57
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
MMP1 P03956 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54
MMP8 P22894 1/20 0.54
MMP13 P45452 1/20 0.54
F13A1 P00488 2/20 0.53
TGM1 P22735 2/20 0.53
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658106 1.00 NPY5R (0.61) NPY5RALDH1A1TBXA2RMEN1KMT2A
SCHEMBL7852578 0.99 MEN1 (0.60) NPY5RALDH1A1TBXA2RMEN1KMT2A
SCHEMBL15548952 0.95 MEN1 (0.61) NPY5RALDH1A1TBXA2RMEN1KMT2A
SCHEMBL4178616 0.89 KMT2A (0.64) NPY5RALDH1A1MEN1KMT2ALMNA
SCHEMBL3540913 0.89 KMT2A (0.66) NPY5RALDH1A1MEN1KMT2ALMNA
SCHEMBL31284709 0.88 KMT2A (0.68) NPY5RALDH1A1MEN1KMT2ALMNA
SCHEMBL7007035 0.87 NPY5R (0.67) NPY5RALDH1A1MEN1KMT2ALMNA
SCHEMBL7014453 0.87 NPY5R (0.67) NPY5RALDH1A1MEN1KMT2ALMNA
SCHEMBL7007042 0.87 NPY5R (0.67) NPY5RALDH1A1MEN1KMT2ALMNA
SCHEMBL1983510 0.87 NPY5R (0.67) NPY5RALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION LE ROUX DANIELLE MARIE (US) 2026-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION VIP, GIPR, SLC10A2 NPY5R 157/4885ALDH1A1 4359/4885TBXA2R 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.